| scholarly article | Q13442814 |
| P2093 | author name string | Carmelo Scarpignato | |
| Iva Pelosini | |||
| P2860 | cites work | Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial | Q44825204 |
| Solution structure of rifaximin and its synthetic derivative rifaximin OR determined by experimental NMR and theoretical simulation methods. | Q44841497 | ||
| Neomycin absorption in man. Studies of oral and enema administration and effect of intestinal ulceration | Q51680695 | ||
| A teratological study of aminoglycoside antibiotic treatment during pregnancy | Q52167133 | ||
| Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom? | Q54122329 | ||
| Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. | Q54624718 | ||
| Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. | Q55033133 | ||
| Evolving therapy for Helicobacter pylori infection | Q57821560 | ||
| Bacterial translocation of enteric organisms in patients with cirrhosis | Q58387749 | ||
| Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective | Q24535810 | ||
| Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea | Q24644390 | ||
| Dysbiosis in inflammatory bowel disease | Q24685931 | ||
| Gut flora in health and disease | Q28209082 | ||
| Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration | Q29547429 | ||
| Helicobacter pylori infection and the development of gastric cancer | Q29615341 | ||
| Pathophysiology and impact of enteric bacterial and protozoal infections: new approaches to therapy | Q30436681 | ||
| Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis | Q30530113 | ||
| The use of rifampicin in staphylococcal infections--a review | Q40184737 | ||
| Bacitracin | Q40245606 | ||
| Recent trends in rifamycin research | Q40388298 | ||
| Resistance of germfree rats to indomethacin-induced intestinal lesions | Q40803813 | ||
| Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: a new mechanism | Q42128208 | ||
| Deafness Complicating Antibiotic Therapy of Hepatic Encephalopathy | Q42238739 | ||
| Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors | Q42272106 | ||
| In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. | Q43627883 | ||
| IAP Guidelines for the Surgical Management of Acute Pancreatitis | Q43750115 | ||
| Towards the ideal regimen for Helicobacter pylori eradication: the search continues | Q43756731 | ||
| Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats | Q43802113 | ||
| Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy | Q44080541 | ||
| Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy | Q44289270 | ||
| Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis | Q44319566 | ||
| Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection | Q44352717 | ||
| Gastrointestinal dysmotility in patients with acute pancreatitis | Q44399675 | ||
| Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas | Q44499393 | ||
| The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial | Q44537495 | ||
| Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug | Q44786104 | ||
| Drug interactions between oral contraceptives and antibiotics | Q31029638 | ||
| Antibiotic side effects | Q31974254 | ||
| A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics | Q33425717 | ||
| Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. | Q33430615 | ||
| Pseudomembranous colitis: causes and cures | Q33545742 | ||
| Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility | Q33593076 | ||
| A review of the role of antibiotic policies in the control of antibiotic resistance | Q33647952 | ||
| Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club | Q33836637 | ||
| Short-term prophylaxis in clean-contaminated surgery | Q33840125 | ||
| Is single-dose antibiotic prophylaxis sufficient for any surgical procedure? | Q33840131 | ||
| Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome | Q33861186 | ||
| The Ames Salmonella/microsome mutagenicity assay | Q33927851 | ||
| Minimizing quinolone resistance: are the new agents more or less likely to cause resistance? | Q33933067 | ||
| In vitro activity and fecal concentration of rifaximin after oral administration | Q33980321 | ||
| In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions | Q33981185 | ||
| Antibiotic susceptibility and resistance testing: an overview | Q34101334 | ||
| Is metronidazole carcinogenic? | Q34132202 | ||
| Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis | Q34141306 | ||
| Antibiotics and anaerobes of gut origin | Q34271679 | ||
| Gut microflora in the pathogenesis of the complications of cirrhosis | Q34318193 | ||
| Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome | Q34341766 | ||
| Infection prevention in necrotizing pancreatitis: an old challenge with new perspectives | Q34342819 | ||
| Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea | Q34389970 | ||
| Spontaneous bacterial peritonitis—diagnosis, treatment and prevention | Q34458940 | ||
| Gastrointestinal infections | Q34486444 | ||
| Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. | Q34504027 | ||
| In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species | Q34509301 | ||
| Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci | Q34552369 | ||
| The pathogenesis of gastrointestinal bacterial overgrowth | Q34557095 | ||
| Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract | Q34557108 | ||
| A 10-year survey of Mycobacterium tuberculosis isolates in Pavia and their drug resistance: a comparison with other Italian reports | Q34562609 | ||
| Treatment of Helicobacter pylori infection. Indications and regimens: an update | Q34583340 | ||
| New perspectives in antibiotic prophylaxis for intra-abdominal surgery | Q34626543 | ||
| Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. | Q34657352 | ||
| Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative | Q34729751 | ||
| Bacterial infection of pancreatic necrosis: role of bacterial translocation, impact of antibiotic treatment | Q34742979 | ||
| Small Intestine Dysmotility and Bacterial Overgrowth in Cirrhotic Patients With Spontaneous Bacterial Peritonitis | Q34754428 | ||
| The role of the gut flora in health and disease, and its modification as therapy | Q34786696 | ||
| Aminoglycoside antibiotic resistance by enzymatic deactivation | Q35014471 | ||
| Chemistry and biology of the ramoplanin family of peptide antibiotics | Q35030299 | ||
| Surgical site infections: epidemiology and prevention | Q35062231 | ||
| Drug excretion into breast milk--overview | Q35111467 | ||
| Review article: the treatment of refractory Helicobacter pylori infection | Q35145092 | ||
| Clostridium difficile infection: responses, relapses and re-infections | Q35270204 | ||
| Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract | Q35551924 | ||
| Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales | Q35553966 | ||
| Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts | Q35563533 | ||
| Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects | Q35596051 | ||
| Bacterial translocation and its prevention in acute pancreatitis | Q35624945 | ||
| Effect of nonsteroidal anti-inflammatory drugs on the gastrointestinal tract: diagnosis by wireless capsule endoscopy | Q35735626 | ||
| Microbial-gut interactions in health and disease. Interactions between dendritic cells and bacteria in the regulation of intestinal immunity | Q35762864 | ||
| Antibiotic resistance from two perspectives: man and microbe | Q35785081 | ||
| Clostridium difficile-associated diarrhea in adults | Q35828291 | ||
| The role of antibiotics in the management of Crohn's disease | Q35854536 | ||
| Antibacterial susceptibility testing in the clinical laboratory | Q35861661 | ||
| Rifaximin: in vitro and in vivo antibacterial activity--a review | Q36108484 | ||
| Rifaximin in the treatment of infectious diarrhea | Q36108487 | ||
| Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials? | Q36108490 | ||
| Management of hepatic encephalopathy: role of rifaximin | Q36108494 | ||
| Management of inflammatory bowel disease: does rifaximin offer any promise? | Q36108499 | ||
| Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin | Q36108503 | ||
| Management of diverticular disease: is there room for rifaximin? | Q36108507 | ||
| Mechanical and antibacterial bowel preparation in colon and rectal surgery | Q36108512 | ||
| In vitro activity of rifaximin, a topical rifamycin derivative, against Chlamydia trachomatis | Q37891596 | ||
| Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin | Q38957462 | ||
| 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures | Q39220539 | ||
| Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly | Q39404301 | ||
| Vancomycin: an update | Q39746652 | ||
| Induction of gene conversion in diploid yeast by chemicals: Correlation with mutagenic action and its relevance in genotoxicity screening | Q39794363 | ||
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 36-66 | |
| P577 | publication date | 2005-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Chemotherapy | Q2440355 |
| P1476 | title | Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential | |
| P478 | volume | 51 Suppl 1 |
| Q33371187 | 'Rescue' therapies for the management of Helicobacter pylori infection |
| Q57703133 | A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosis |
| Q90227921 | Actinomycete-Derived Polyketides as a Source of Antibiotics and Lead Structures for the Development of New Antimicrobial Drugs |
| Q61805254 | Alternative eradication regimens for infection in Indonesian regions with high metronidazole and levofloxacin resistance |
| Q50794710 | Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy |
| Q39140934 | Anti-inflammatory and immunomodulatory activities of rifamycin SV |
| Q34566470 | Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. |
| Q92309963 | Antibiotics and probiotics in inflammatory bowel disease: when to use them? |
| Q35691133 | Antibiotics for the treatment of irritable bowel syndrome |
| Q35558415 | Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome? |
| Q99929789 | Colonic diverticular disease |
| Q52662081 | Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management. |
| Q39665248 | Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance |
| Q84977369 | Diverticular Disease: Eat Your Fiber! |
| Q26775927 | Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications |
| Q64248000 | Effective therapeutic regimens in two South Asian countries with high resistance to major antibiotics |
| Q39781817 | Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis |
| Q46604531 | Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations |
| Q91783880 | Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese |
| Q36171542 | Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota |
| Q41990739 | Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients |
| Q38424698 | Emerging therapies for the treatment of Helicobacter pylori infections |
| Q36659957 | Emerging therapies in the treatment of Clostridium difficile-associated disease |
| Q39455595 | Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation |
| Q41124468 | Formulation and Development of Extended-Release Micro Particulate Drug Delivery System of Solubilized Rifaximin |
| Q37478838 | High Prevalence of Antibiotic-Resistant Bacterial Infections Among Patients With Cirrhosis at a US Liver Center |
| Q61387945 | High gastrointestinal permeability and local metabolism of naringenin: influence of antibiotic treatment on absorption and metabolism |
| Q34757166 | Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers. |
| Q92032230 | Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives |
| Q58556501 | Locally Used Antibiotics for Spinal Infection Prophylaxis and Their Effects on Epidural Fibrosis: an Experimental Laminectomy Study in Rats Using Rifamycin and Gentamycin |
| Q54965289 | Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. |
| Q38633511 | Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies |
| Q99414159 | New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress |
| Q37800668 | Nonsteroidal Antiinflammatory Drug-Related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and Prevention |
| Q36674768 | Past, present, and future therapies for Clostridium difficile-associated disease |
| Q93162080 | Pathogen-targeting glycovesicles as a therapy for salmonellosis |
| Q59800501 | Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention |
| Q37762245 | Pharmacotherapy for hepatic encephalopathy |
| Q39659623 | Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells |
| Q42407730 | Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. |
| Q26829363 | Profile of rifaximin and its potential in the treatment of irritable bowel syndrome |
| Q35855740 | Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea |
| Q35855737 | Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases |
| Q46319853 | Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. |
| Q39428832 | Rifamycin SV MMX for the treatment of traveler's diarrhea |
| Q40652722 | Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB Pathway |
| Q47118655 | Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity |
| Q24187627 | Rifaximin for people with hepatic encephalopathy |
| Q38340085 | Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. |
| Q42776121 | Rifaximin for the treatment of hepatic encephalopathy |
| Q37976477 | Rifaximin for the treatment of irritable bowel syndrome |
| Q36009729 | Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. |
| Q38696806 | Rifaximin has minor effects on bacterial composition, inflammation and bacterial translocation in cirrhosis; A randomized trial |
| Q48462438 | Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. |
| Q39295479 | Rifaximin in the management of colonic diverticular disease |
| Q43010964 | Rifaximin in the treatment of inflammatory bowel disease |
| Q45573898 | Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. |
| Q34607677 | Rifaximin pharmacology and clinical implications |
| Q39901709 | Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation |
| Q42324150 | Rifaximin therapy and hepatic encephalopathy: Pros and cons |
| Q34588803 | Rifaximin treatment for symptoms of irritable bowel syndrome |
| Q41698366 | Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review |
| Q34579745 | Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. |
| Q34557108 | Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract |
| Q36214684 | Rifaximin: a review of its use in the management of traveller's diarrhoea |
| Q33958376 | Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials |
| Q28236913 | Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy |
| Q26829666 | Second and third line treatment options for Helicobacter pylori eradication |
| Q27001540 | Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver |
| Q39081757 | Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth |
| Q28660009 | The impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trials |
| Q39035437 | The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. |
| Q34557095 | The pathogenesis of gastrointestinal bacterial overgrowth |
| Q37564122 | Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders |
| Q36521201 | Use of antibiotics in the treatment of inflammatory bowel disease |
| Q26740201 | Use of rifaximin in gastrointestinal and liver diseases |
Search more.